{"id":"lorcaserin","rwe":[],"tags":[{"label":"Serotonin-2c Receptor Agonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2C","category":"target"},{"label":"HTR2C","category":"gene"},{"label":"HTR2A","category":"gene"},{"label":"HTR2B","category":"gene"},{"label":"A08AA11","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Obesity","category":"indication"},{"label":"Eisai Inc","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"safetySignals":[{"llr":145.839,"date":"","count":113,"signal":"Headache","source":"DrugCentral FAERS","actionTaken":"Reported 113 times (LLR=146)"},{"llr":85.751,"date":"","count":75,"signal":"Dizziness","source":"DrugCentral FAERS","actionTaken":"Reported 75 times (LLR=86)"},{"llr":72.505,"date":"","count":94,"signal":"Fatigue","source":"DrugCentral FAERS","actionTaken":"Reported 94 times (LLR=73)"}],"drugInteractions":[{"url":"/drug/tamoxifen","drug":"tamoxifen","action":"Monitor closely","effect":"May interact with Tamoxifen","source":"DrugCentral","drugSlug":"tamoxifen"}],"commonSideEffects":[],"contraindications":["Pregnancy, function"],"specialPopulations":{"Lactation":"Use of BELVIQ/BELVIQ XR is not recommended while breastfeeding.","Pregnancy":"BELVIQ/BELVIQ XR is contraindicated during pregnancy, because weight loss offers no benefit to pregnant woman and may result in fetal harm. Limited data on lorcaserin use in pregnant women are not sufficient to determine drug-associated risk of major congenital malformations or miscarriage.","Geriatric use":"In the BELVIQ clinical trials, total of 135 (2.5%) of the patients were 65 years of age and older. Clinical studies of BELVIQ did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"The safety and effectiveness of BELVIQ/BELVIQ XR in pediatric patients below the age of 18 have not been established and the use of BELVIQ/BELVIQ XR is not recommended in pediatric patients.","Renal impairment":"Use of BELVIQ/BELVIQ XR in the elderly should be made on the basis of renal function"}},"trials":[],"aliases":[],"company":"Eisai","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LORCASERIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:21:18.572793+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Lorcaserin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:21:25.573729+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:21:24.165066+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LORCASERIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:21:24.512692+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL360328/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:25.204566+00:00"}},"allNames":"belviq","offLabel":[],"synonyms":["lorcaserin hydrochloride hemihydrate","lorcaserin hydrochloride","belviq","lorcaserin","lorcaserin HCl","APD356","APD 356","APD-356"],"timeline":[{"date":"2012-06-27","type":"positive","source":"DrugCentral","milestone":"FDA approval (Eisai Inc)"}],"approvals":[{"date":"2012-06-27","orphan":false,"company":"EISAI INC","regulator":"FDA"}],"brandName":"Belviq","ecosystem":[{"indication":"Obesity","otherDrugs":[{"name":"amfetamine","slug":"amfetamine","company":"Ucb Inc"},{"name":"benzphetamine","slug":"benzphetamine","company":"Pharmacia And Upjohn"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"chlorphentermine","slug":"chlorphentermine","company":"Parke Davis"}],"globalPrevalence":890000000}],"mechanism":{"target":"5-hydroxytryptamine receptor 2C","novelty":"Follow-on","targets":[{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"}],"moaClass":"Cytochrome P450 2D6 Inhibitors","modality":"Small Molecule","drugClass":"Serotonin-2c Receptor Agonist","explanation":"","oneSentence":"","technicalDetail":"Lorcaserin acts as a selective agonist of the 5-hydroxytryptamine receptor 2C (5-HT2C), a subtype of serotonin receptor, to modulate appetite and satiety centers in the brain."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Lorcaserin","title":"Lorcaserin","extract":"Lorcaserin, marketed under the brand name Belviq, was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating the 5-HT2C serotonin receptor in the hypothalamus, a region of the brain which is known to control appetite. It was approved in 2012, and in 2020 was removed from the market in the United States due to an increased risk of cancer detected in users of Belviq.","wiki_history":"==History==\n===Approval history===\nOn 22 December 2009, a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States. On 23 October 2010, the FDA decided not to approve the drug based on the available data. This was not only because cancer promoting properties could not be ruled out, but also because the weight loss efficacy was considered \"marginal\".\n\nOn 10 May 2012, after a new round of studies submitted by Arena, an FDA panel voted to recommend lorcaserin with certain restrictions and patient monitoring. The restrictions include patients with a BMI of over 30, or with a BMI over 27 and a comorbidity such as high blood pressure or type 2 diabetes. \n\nOn 27 June 2012, the FDA approved lorcaserin for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who had at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).\n\nOn 15 July 2016, the FDA approved the extended release version of lorcaserin for weight management with once-daily dosing instead of twice daily dosing.\n\nOn 17 September 2020, the FDA withdrew approval for lorcaserin and for extended-release lorcaserin tablets.","wiki_society_and_culture":"==Society and culture==\n===Legal status===\n====Canada====\nLorcaserin is not a controlled substance in Canada.\n\n====United States====\nIn December 2012, the US Drug Enforcement Administration proposed classifying lorcaserin as a Schedule IV drug because it has hallucinogenic properties at higher than approved doses and users hypothetically might develop psychiatric dependencies on the drug. On 7 May 2013, the US Drug Enforcement Administration classified lorcaserin as a Schedule IV drug under the Controlled Substances Act."},"commercial":{"launchDate":"2012","_launchSource":"DrugCentral (FDA 2012-06-27, EISAI INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4374","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LORCASERIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LORCASERIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Lorcaserin","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T15:00:25.828013","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:26.983490+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"phentermine","drugSlug":"phentermine","fdaApproval":"1959-05-04","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenfluramine","drugSlug":"fenfluramine","fdaApproval":"2020-06-25","patentExpiry":"Nov 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"diethylpropion","drugSlug":"diethylpropion","fdaApproval":"1959-08-06","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mazindol","drugSlug":"mazindol","fdaApproval":"1973-06-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"sibutramine","drugSlug":"sibutramine","fdaApproval":"1997-11-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"setmelanotide","drugSlug":"setmelanotide","fdaApproval":"2020-11-25","patentExpiry":"Oct 13, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"topiramate","drugSlug":"topiramate","fdaApproval":"1996-12-24","patentExpiry":"Nov 16, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ephedrine","drugSlug":"ephedrine","fdaApproval":"","patentExpiry":"May 16, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bupropion","drugSlug":"bupropion","fdaApproval":"1985-12-30","patentExpiry":"Jun 27, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"naltrexone","drugSlug":"naltrexone","fdaApproval":"1984-11-20","patentExpiry":"Oct 15, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"lorcaserin","indications":{"approved":[{"name":"Obesity","source":"DrugCentral","snomedId":414916001,"regulator":"FDA","eligibility":{"BMI":"30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type diabetes)"},"usPrevalence":100000000,"globalPrevalence":890000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"phentermine","brandName":"phentermine","genericName":"phentermine","approvalYear":"1959","relationship":"same-class"},{"drugId":"fenfluramine","brandName":"fenfluramine","genericName":"fenfluramine","approvalYear":"2020","relationship":"same-class"},{"drugId":"diethylpropion","brandName":"diethylpropion","genericName":"diethylpropion","approvalYear":"1959","relationship":"same-class"},{"drugId":"mazindol","brandName":"mazindol","genericName":"mazindol","approvalYear":"1973","relationship":"same-class"},{"drugId":"sibutramine","brandName":"sibutramine","genericName":"sibutramine","approvalYear":"1997","relationship":"same-class"},{"drugId":"setmelanotide","brandName":"setmelanotide","genericName":"setmelanotide","approvalYear":"2020","relationship":"same-class"},{"drugId":"topiramate","brandName":"topiramate","genericName":"topiramate","approvalYear":"1996","relationship":"same-class"},{"drugId":"ephedrine","brandName":"ephedrine","genericName":"ephedrine","approvalYear":"","relationship":"same-class"},{"drugId":"bupropion","brandName":"bupropion","genericName":"bupropion","approvalYear":"1985","relationship":"same-class"},{"drugId":"naltrexone","brandName":"naltrexone","genericName":"naltrexone","approvalYear":"1984","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03266939","phase":"PHASE1","title":"Rebalancing the Serotonergic System in Cocaine Dependence","status":"WITHDRAWN","sponsor":"Mclean Hospital","startDate":"2018-10-04","conditions":["Cocaine Dependence"],"enrollment":0,"completionDate":"2018-10-04"},{"nctId":"NCT04572243","phase":"PHASE3","title":"A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2020-09-23","conditions":["Epilepsies, Myoclonic"],"enrollment":22,"completionDate":"2024-08-15"},{"nctId":"NCT06090461","phase":"","title":"Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)","status":"COMPLETED","sponsor":"Currax Pharmaceuticals","startDate":"2014-09","conditions":["Obesity"],"enrollment":31889,"completionDate":"2022-12"},{"nctId":"NCT02400359","phase":"PHASE4","title":"Lorcaserin in Obesity: Identification of CNS Targets Using FMRI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2014-10","conditions":["Obesity","Weight Loss"],"enrollment":40,"completionDate":"2026-03"},{"nctId":"NCT04457687","phase":"","title":"Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies","status":"AVAILABLE","sponsor":"Eisai Inc.","startDate":"","conditions":["Epilepsies, Myoclonic","Drug Resistant Epilepsy"],"enrollment":0,"completionDate":""},{"nctId":"NCT03353220","phase":"PHASE4","title":"Predictors of Lorcaserin-Induced Weight Loss","status":"TERMINATED","sponsor":"Columbia University","startDate":"2018-01-03","conditions":["Overweight and Obesity"],"enrollment":32,"completionDate":"2020-02-14"},{"nctId":"NCT03192995","phase":"PHASE2","title":"Treatment With Lorcaserin for Cocaine Use: The TLC Study","status":"TERMINATED","sponsor":"Glenn-Milo Santos","startDate":"2018-01-01","conditions":["Cocaine Use Disorder"],"enrollment":22,"completionDate":"2020-06-30"},{"nctId":"NCT00828581","phase":"PHASE1","title":"Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-10","conditions":["Obesity"],"enrollment":24,"completionDate":"2008-12"},{"nctId":"NCT04396834","phase":"PHASE2","title":"Mechanisms of Lorcaserin for Smoking Cessation","status":"TERMINATED","sponsor":"The Mind Research Network","startDate":"2019-12-04","conditions":["Tobacco Use Disorder","Smoking Cessation"],"enrollment":3,"completionDate":"2020-02-26"},{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":["Obesity"],"enrollment":200,"completionDate":"2020-05-22"},{"nctId":"NCT04396847","phase":"PHASE2","title":"Laboratory Screening of Lorcaserin for Alcohol Use Disorder","status":"TERMINATED","sponsor":"The Mind Research Network","startDate":"2019-10-25","conditions":["Alcohol Use Disorder","Tobacco Smoking"],"enrollment":5,"completionDate":"2020-02-26"},{"nctId":"NCT03253926","phase":"PHASE1,PHASE2","title":"Effect of Lorcaserin on Cannabis Withdrawal and Self-administration","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2017-09-05","conditions":["Cannabis Use"],"enrollment":15,"completionDate":"2021-12-31"},{"nctId":"NCT03720574","phase":"PHASE3","title":"Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients","status":"TERMINATED","sponsor":"Kanion & Huawe Medicine Co.,Ltd","startDate":"2019-09-17","conditions":["Obesity"],"enrollment":100,"completionDate":"2020-12-12"},{"nctId":"NCT03338296","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2017-09-28","conditions":["Obesity"],"enrollment":278,"completionDate":"2020-04-03"},{"nctId":"NCT02412631","phase":"PHASE2,PHASE3","title":"Addressing Post Cessation Weight Gain","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-06-15","conditions":["Obesity","Smoking Cessation"],"enrollment":84,"completionDate":"2020-04-17"},{"nctId":"NCT02796144","phase":"PHASE4","title":"MEtformin and Lorcaserin for WeighT Loss in Schizophrenia","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-09","conditions":["Schizophrenia","Schizoaffective Disorder","Overweight"],"enrollment":71,"completionDate":"2020-02-14"},{"nctId":"NCT03637842","phase":"EARLY_PHASE1","title":"Lorcaserin for Cannabis Use Disorder","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-08-01","conditions":["Cannabis Use Disorder"],"enrollment":5,"completionDate":"2020-02-29"},{"nctId":"NCT04205071","phase":"PHASE1","title":"Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer","status":"WITHDRAWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2020-11-01","conditions":["Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Chemotherapy-Induced Peripheral Neuropathy","Digestive System Carcinoma","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8"],"enrollment":0,"completionDate":"2021-12-31"},{"nctId":"NCT03143855","phase":"PHASE1","title":"Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2017-01-30","conditions":["Opioid Abuse","Opioid Dependence","Opioid-Related Disorders","Opioid Use"],"enrollment":32,"completionDate":"2019-04-05"},{"nctId":"NCT03169816","phase":"PHASE2,PHASE3","title":"Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2017-05-25","conditions":["Opioid-use Disorder"],"enrollment":60,"completionDate":"2019-08-30"},{"nctId":"NCT03007394","phase":"PHASE2","title":"Lorcaserin in the Treatment of Cocaine Use Disorder","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2017-12-19","conditions":["Cocaine-Related Disorders"],"enrollment":272,"completionDate":"2019-12-01"},{"nctId":"NCT02537873","phase":"PHASE1","title":"Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2015-07","conditions":["Cocaine Use Disorder"],"enrollment":29,"completionDate":"2018-07-19"},{"nctId":"NCT03143543","phase":"PHASE1","title":"Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2015-07","conditions":["Cocaine-Related Disorders","Opioid-Related Disorders"],"enrollment":171,"completionDate":"2019-12-06"},{"nctId":"NCT03011645","phase":"PHASE1","title":"Gene-by-Stress Interactions in Intervention Studies Significance","status":"TERMINATED","sponsor":"Duke University","startDate":"2018-05-24","conditions":["Cardiovascular Diseases"],"enrollment":7,"completionDate":"2020-01-28"},{"nctId":"NCT02523690","phase":"PHASE1,PHASE2","title":"Evaluating Muscle Weakness Improvement With Lorcaserin in ICU","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2015-12","conditions":["Muscle Weakness","Sepsis"],"enrollment":5,"completionDate":"2017-12"},{"nctId":"NCT03552107","phase":"","title":"Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic","status":"COMPLETED","sponsor":"Scripps Whittier Diabetes Institute","startDate":"2017-04-11","conditions":["Obesity","Weight Loss","Overweight"],"enrollment":157,"completionDate":"2019-04-11"},{"nctId":"NCT02932215","phase":"PHASE1","title":"Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2016-10","conditions":["Cannabis Use Disorder"],"enrollment":17,"completionDate":"2019-01-17"},{"nctId":"NCT00603902","phase":"PHASE3","title":"BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-01","conditions":["Obesity"],"enrollment":4008,"completionDate":"2009-08"},{"nctId":"NCT00603291","phase":"PHASE3","title":"BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-12","conditions":["Obesity"],"enrollment":604,"completionDate":"2010-10"},{"nctId":"NCT00395135","phase":"PHASE3","title":"BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-11","conditions":["Obesity"],"enrollment":3182,"completionDate":"2009-02"},{"nctId":"NCT01987427","phase":"PHASE4","title":"A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2013-10-30","conditions":["Chronic Weight Management"],"enrollment":344,"completionDate":"2014-09-03"},{"nctId":"NCT02022956","phase":"PHASE1","title":"Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2013-12","conditions":["Pharmacokinetics in Obese Adolescents"],"enrollment":8,"completionDate":""},{"nctId":"NCT00828438","phase":"PHASE1","title":"Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-10","conditions":["Renal Impairment"],"enrollment":40,"completionDate":"2009-02"},{"nctId":"NCT00828724","phase":"PHASE1","title":"Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-11","conditions":["Obesity"],"enrollment":24,"completionDate":"2008-12"},{"nctId":"NCT00828659","phase":"PHASE1","title":"Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-12","conditions":["Drug Abuse","Healthy"],"enrollment":35,"completionDate":"2009-04"},{"nctId":"NCT00104507","phase":"PHASE2","title":"Safety and Efficacy of APD356 in the Treatment of Obesity","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2004-12","conditions":["Obesity"],"enrollment":400,"completionDate":"2005-05"},{"nctId":"NCT00828932","phase":"PHASE1","title":"Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-08","conditions":["Hepatic Impairment"],"enrollment":24,"completionDate":"2008-12"},{"nctId":"NCT00829140","phase":"PHASE1","title":"To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-11","conditions":["Obesity"],"enrollment":56,"completionDate":"2010-02"},{"nctId":"NCT00116740","phase":"PHASE2","title":"Safety and Efficacy of APD356 in the Treatment of Obesity","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-06","conditions":["Obesity"],"enrollment":400,"completionDate":"2005-11"},{"nctId":"NCT02019264","phase":"PHASE4","title":"A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2014-01-24","conditions":["Cardiovascular Disease","High Cardiovascular Risk","Obesity","Overweight","Type 2 Diabetes"],"enrollment":14673,"completionDate":"2018-05-14"},{"nctId":"NCT02906644","phase":"PHASE2","title":"Combination Nicotine Patch / Lorcaserin for Smoking Cessation","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-11-08","conditions":["Nicotine Dependence"],"enrollment":97,"completionDate":"2018-10-18"},{"nctId":"NCT02044874","phase":"PHASE2","title":"A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation","status":"COMPLETED","sponsor":"Arena Pharmaceuticals","startDate":"2014-03","conditions":["Smoking Cessation"],"enrollment":603,"completionDate":"2014-11"},{"nctId":"NCT03812523","phase":"PHASE2","title":"Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Southeastern Regional Medical Center","startDate":"2019-06","conditions":["Chemotherapy-Induced Peripheral Neuropathy"],"enrollment":50,"completionDate":"2021-10"},{"nctId":"NCT03741010","phase":"","title":"Belviq Tablet® Post Marketing Surveillance Protocol","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-02-02","conditions":["Weight Loss"],"enrollment":3000,"completionDate":"2021-02-01"},{"nctId":"NCT03627936","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-08-07","conditions":["Healthy Participants"],"enrollment":40,"completionDate":"2018-09-02"},{"nctId":"NCT02388568","phase":"NA","title":"Lifestyle Modification and Lorcaserin for Weight Loss Maintenance","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2015-01","conditions":["Obesity"],"enrollment":137,"completionDate":"2017-06"},{"nctId":"NCT02393547","phase":"PHASE1,PHASE2","title":"Lorcaserin for Preventing Weight Gain Among Smokers","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-09","conditions":["Tobacco Use Disorder","Weight Gain"],"enrollment":20,"completionDate":"2015-12"},{"nctId":"NCT02393599","phase":"PHASE1","title":"Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2015-05","conditions":["Cocaine Abuse"],"enrollment":20,"completionDate":"2015-09"},{"nctId":"NCT02129608","phase":"PHASE3","title":"Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-06","conditions":["Overweight","Obese"],"enrollment":44,"completionDate":"2015-12"},{"nctId":"NCT02680288","phase":"PHASE1,PHASE2","title":"Lorcaserin Intra Venous Cocaine Effects","status":"UNKNOWN","sponsor":"Midwest Biomedical Research Foundation","startDate":"2015-11","conditions":["Cocaine Use Disorders"],"enrollment":32,"completionDate":"2019-11"},{"nctId":"NCT02192515","phase":"PHASE1","title":"A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2014-07","conditions":["Healthy Subjects"],"enrollment":40,"completionDate":"2016-01"},{"nctId":"NCT02398669","phase":"PHASE1","title":"A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2015-03","conditions":["Obesity"],"enrollment":10,"completionDate":"2015-05"},{"nctId":"NCT01962402","phase":"PHASE4","title":"Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study","status":"UNKNOWN","sponsor":"Southern California Institute for Research and Education","startDate":"2014-01","conditions":["Weight Gain"],"enrollment":15,"completionDate":""},{"nctId":"NCT01880502","phase":"PHASE1","title":"Pharmacokinetic Study of Belviq in Adult Korean Volunteers","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-06","conditions":["Healthy"],"enrollment":25,"completionDate":"2013-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Belviq"},{"form":"TABLET, FILM COATED, EXTENDED RELEASE","route":"ORAL","productName":"BELVIQ  XR Extended ReleaseExtended Release"}]},"crossReferences":{"NUI":"N0000187068","MMSL":"191544","NDDF":"015054","UNII":"637E494O0Z","VUID":"4032466","CHEBI":"CHEBI:65353","VANDF":"4032466","INN_ID":"8765","RXNORM":"1300700","UMLSCUI":"C2350948","chemblId":"CHEMBL360328","ChEMBL_ID":"CHEMBL360328","KEGG_DRUG":"D06613","DRUGBANK_ID":"DB04871","PDB_CHEM_ID":" T4U","PUBCHEM_CID":"11658860","SNOMEDCT_US":"716226007","IUPHAR_LIGAND_ID":"2941","SECONDARY_CAS_RN":"856681-05-5","MESH_SUPPLEMENTAL_RECORD_UI":"C506658"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED, EXTENDED RELEASE","route":"ORAL","company":"Eisai Inc.","brandName":"BELVIQ  XR Extended ReleaseExtended Release","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2012-","companyName":"Eisai Inc","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","fractionUnbound":"0.058%"},"publicationCount":494,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A08AA11","allCodes":["A08AA11"]},"biosimilarFilings":[],"originalDeveloper":"Eisai Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"Eisai","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"2012","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-06-27T00:00:00.000Z","mah":"EISAI INC","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2012-06-27T00:00:00.000Z","mah":"EISAI INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2012-06-27T00:00:00.000Z","mah":"EISAI INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2012-06-27T00:00:00.000Z","mah":"EISAI INC","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2012-06-27T00:00:00.000Z","mah":"EISAI INC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2012-06-27T00:00:00.000Z","mah":"EISAI INC","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:26.983490+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}